v3.26.1
SEGMENT REPORTING (Tables)
 12 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of significant expense categories
        
Category 

Year Ended

March 31, 2026

   Year Ended
March 31, 2025		 
Research and development1  $1,912,000   $2,212,000 
General and administrative2  $2,696,000   $3,243,000 
Cash used in operating activities3  $6,998,000   $7,646,000 

 

1 Research and development expenses primarily include costs related to laboratory operations, clinical trial execution, investigational device testing, design iterations, and personnel expenses associated with research activities. These costs are recorded within payroll, professional fees, and general and administrative (“G&A”) expense on the face of the statements of operations, as the Company does not maintain a separate R&D line item.
   
2 General and administrative expenses encompass overhead, administrative costs associated with clinical trial operations, and certain manufacturing-related costs. R&D costs are included within these categories for financial reporting purposes and are not separately reclassified.
   
3 Cash used in operating activities is the key internal performance metric tracked by the CODM to evaluate development progress, cash needs, and investment strategy in the absence of commercial revenue.